liposomal interleukin-2 (Taiwan Liposome Company)

Liposomal interleukin-2 (L-IL-2) is a lipid-encapsulated formulation of recombinant interleukin-2 (aldesleukin) designed to improve the therapeutic index of IL-2 therapy. Interleukin-2 is a potent cytokine that stimulates the proliferation and activation of T cells and natural killer (NK) cells, which are critical for anti-tumor immunity. However, high-dose systemic administration of free IL-2 is associated with severe toxicities, most notably vascular leak syndrome (VLS). By encapsulating the cytokine in liposomes, L-IL-2 aims to alter the pharmacokinetics and biodistribution of the drug, potentially reducing systemic toxicity while maintaining or enhancing anti-tumor efficacy through sustained release and improved delivery to lymphoid tissues and tumor sites. It has been investigated primarily for the treatment of metastatic melanoma and renal cell carcinoma.

Other names

Liposomal IL-2Liposomal aldesleukin